RU2019126574A - Потенциаторы рецепторов ampa - Google Patents
Потенциаторы рецепторов ampa Download PDFInfo
- Publication number
- RU2019126574A RU2019126574A RU2019126574A RU2019126574A RU2019126574A RU 2019126574 A RU2019126574 A RU 2019126574A RU 2019126574 A RU2019126574 A RU 2019126574A RU 2019126574 A RU2019126574 A RU 2019126574A RU 2019126574 A RU2019126574 A RU 2019126574A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- paragraphs
- connection according
- disorder
- compound
- Prior art date
Links
- 102000003678 AMPA Receptors Human genes 0.000 title claims 3
- 108090000078 AMPA Receptors Proteins 0.000 title claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000009540 excitatory neurotransmission Effects 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000009539 inhibitory neurotransmission Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000036630 mental development Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003956 synaptic plasticity Effects 0.000 claims 1
- -1 —CH (CH 3 ) OH Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1702221.1 | 2017-02-10 | ||
| GBGB1702221.1A GB201702221D0 (en) | 2017-02-10 | 2017-02-10 | Compounds |
| PCT/GB2018/050370 WO2018146486A1 (en) | 2017-02-10 | 2018-02-09 | Ampa receptor potentiators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019126574A true RU2019126574A (ru) | 2021-03-10 |
| RU2019126574A3 RU2019126574A3 (OSRAM) | 2021-03-29 |
Family
ID=58462168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019126574A RU2019126574A (ru) | 2017-02-10 | 2018-02-09 | Потенциаторы рецепторов ampa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11186567B2 (OSRAM) |
| EP (1) | EP3580213B1 (OSRAM) |
| JP (1) | JP7014808B2 (OSRAM) |
| KR (1) | KR102665887B1 (OSRAM) |
| CN (1) | CN110520418B (OSRAM) |
| AU (1) | AU2018218307C1 (OSRAM) |
| ES (1) | ES2974824T3 (OSRAM) |
| GB (1) | GB201702221D0 (OSRAM) |
| MX (1) | MX2019009537A (OSRAM) |
| NZ (1) | NZ755747A (OSRAM) |
| RU (1) | RU2019126574A (OSRAM) |
| WO (1) | WO2018146486A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| WO2024255822A1 (zh) * | 2023-06-15 | 2024-12-19 | 上海魁特迪生物科技有限公司 | Dir结合剂及其用途 |
| CN121652294A (zh) * | 2026-02-06 | 2026-03-13 | 首都医科大学宣武医院 | 一种用于检测抗ampar1抗体的融合蛋白及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| ES2320973T3 (es) | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| CA2646585A1 (en) | 2006-03-20 | 2007-09-27 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| EA016415B1 (ru) | 2006-04-24 | 2012-04-30 | Эли Лилли Энд Компани | Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1 |
| TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| DE602007013450D1 (de) * | 2006-11-03 | 2011-05-05 | Glaxo Group Ltd | Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711088D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| JP5470557B2 (ja) | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| EP2195303A4 (en) | 2007-09-20 | 2011-07-20 | Cortex Pharma Inc | 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| JP5696037B2 (ja) | 2008-05-01 | 2015-04-08 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| BRPI1014583B1 (pt) | 2009-06-26 | 2020-03-31 | Pfizer, Inc. | Sulfonamidas heterocíclicas e composições farmacêuticas |
| WO2011132051A2 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2017
- 2017-02-10 GB GBGB1702221.1A patent/GB201702221D0/en not_active Ceased
-
2018
- 2018-02-09 US US16/482,791 patent/US11186567B2/en active Active
- 2018-02-09 KR KR1020197024520A patent/KR102665887B1/ko active Active
- 2018-02-09 MX MX2019009537A patent/MX2019009537A/es unknown
- 2018-02-09 RU RU2019126574A patent/RU2019126574A/ru unknown
- 2018-02-09 WO PCT/GB2018/050370 patent/WO2018146486A1/en not_active Ceased
- 2018-02-09 NZ NZ755747A patent/NZ755747A/en unknown
- 2018-02-09 CN CN201880023973.3A patent/CN110520418B/zh active Active
- 2018-02-09 JP JP2019543832A patent/JP7014808B2/ja active Active
- 2018-02-09 AU AU2018218307A patent/AU2018218307C1/en active Active
- 2018-02-09 ES ES18705480T patent/ES2974824T3/es active Active
- 2018-02-09 EP EP18705480.4A patent/EP3580213B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018218307C1 (en) | 2022-06-23 |
| ES2974824T3 (es) | 2024-07-01 |
| CN110520418B (zh) | 2022-08-16 |
| JP7014808B2 (ja) | 2022-02-01 |
| JP2020507592A (ja) | 2020-03-12 |
| US11186567B2 (en) | 2021-11-30 |
| MX2019009537A (es) | 2019-10-04 |
| WO2018146486A1 (en) | 2018-08-16 |
| AU2018218307B2 (en) | 2022-02-24 |
| NZ755747A (en) | 2022-02-25 |
| CA3051647A1 (en) | 2018-08-16 |
| EP3580213B1 (en) | 2024-03-27 |
| CN110520418A (zh) | 2019-11-29 |
| BR112019016603A2 (pt) | 2020-03-31 |
| KR20190117549A (ko) | 2019-10-16 |
| AU2018218307A1 (en) | 2019-08-15 |
| EP3580213A1 (en) | 2019-12-18 |
| KR102665887B1 (ko) | 2024-05-10 |
| EP3580213C0 (en) | 2024-03-27 |
| US20210139463A1 (en) | 2021-05-13 |
| RU2019126574A3 (OSRAM) | 2021-03-29 |
| GB201702221D0 (en) | 2017-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019126574A (ru) | Потенциаторы рецепторов ampa | |
| PH12020550631A1 (en) | New catecholamine prodrugs for use in the treatment of parkinson`s disease | |
| MX375424B (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl | |
| RU2017145646A (ru) | Производное пиперидина, способ его получения и его фармацевтическое применение | |
| MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| JP2015501783A5 (OSRAM) | ||
| RU2012140148A (ru) | (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения | |
| JP2013536833A5 (OSRAM) | ||
| MX387207B (es) | Inhibidores de proteína quinasa, método de preparación y su uso médico. | |
| RU2013113634A (ru) | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств | |
| JP2020507592A5 (OSRAM) | ||
| MX392132B (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mG1uR2, COMPOSICIONES Y SU USO. | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| BR112015024472A2 (pt) | derivados de quinolina multifuncionais como agentes anti-neurodegenerativos | |
| RU2020127537A (ru) | Соединения, которые модулируют функцию ampa-рецептора | |
| JP2021515749A5 (OSRAM) | ||
| RU2008102154A (ru) | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, ЛЕКАРСТВЕННАЯ СУБСТАНЦИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| FI3909568T3 (fi) | Profylaktinen tai terapeuttinen lääke neurodegeneratiivisiin tauteihin | |
| RU2018126187A (ru) | Композиции полигидроксилированных бензофенонов и способы лечения нейродегенеративных расстройств | |
| NZ764717B2 (en) | New catecholamine prodrugs for use in the treatment of parkinson's disease | |
| RU2020106762A (ru) | Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний | |
| GR1009143B (el) | Πρωτοτυπη θεραπευτικη δραση επιλεγμενων αμινοτετραϋδροφουρανιων κατα των νευροεκφυλιστικων και των διαχυτων νευροαναπτυξιακων ασθενειων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |